Last update 15 Jul 2024

Tegafur/Gimeracil/Oteracil Potassium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CDHP/potassium-oxonate/tegafur, CIDU/potassium-oxonate/tegafur, Gimeracil/oteracil/tegafur
+ [28]
Target
Mechanism
TYMS inhibitors(Thymidylate synthase inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
JP (04 Apr 2001),
RegulationOrphan Drug (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC17H16ClFKN6O9
InChIKeyORQJWXCFMDIHOO-UHFFFAOYSA-N
CAS Registry150863-82-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hormone receptor positive HER2 negative breast cancer
JP
07 Jun 2023
Hormone receptor positive HER2 negative breast cancer
JP
07 Jun 2023
HER2-negative breast cancer
JP
15 Feb 2017
Advanced gastric carcinoma
EU
14 Mar 2011
Advanced gastric carcinoma
IS
14 Mar 2011
Advanced gastric carcinoma
LI
14 Mar 2011
Advanced gastric carcinoma
NO
14 Mar 2011
Metastatic Colorectal Carcinoma
EU
14 Mar 2011
Metastatic Colorectal Carcinoma
IS
14 Mar 2011
Metastatic Colorectal Carcinoma
LI
14 Mar 2011
Metastatic Colorectal Carcinoma
NO
14 Mar 2011
Stomach Cancer
CN
19 Dec 2008
Biliary Tract Neoplasms
JP
23 Aug 2007
Pancreatic Cancer
JP
10 Aug 2006
Breast Cancer
JP
14 Nov 2005
Non-Small Cell Lung Cancer
JP
14 Dec 2004
Colorectal Cancer
JP
17 Dec 2003
Head and Neck Neoplasms
JP
04 Apr 2001
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastrooesophageal junction cancerPhase 3
US
14 Apr 2011
Gastrooesophageal junction cancerPhase 3
AR
14 Apr 2011
Gastrooesophageal junction cancerPhase 3
BE
14 Apr 2011
Gastrooesophageal junction cancerPhase 3
BR
14 Apr 2011
Gastrooesophageal junction cancerPhase 3
BG
14 Apr 2011
Gastrooesophageal junction cancerPhase 3
HR
14 Apr 2011
Gastrooesophageal junction cancerPhase 3
EE
14 Apr 2011
Gastrooesophageal junction cancerPhase 3
DE
14 Apr 2011
Gastrooesophageal junction cancerPhase 3
HU
14 Apr 2011
Gastrooesophageal junction cancerPhase 3
IL
14 Apr 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
49
Neoadjuvant S-1/Cisplatin-based chemoradiotherapy
tdcqvwiyfg(qrzrwiohsv) = enkblkasyx houcbhnonj (pxecoqsscw )
Positive
24 May 2024
tdcqvwiyfg(qrzrwiohsv) = mptnezbact houcbhnonj (pxecoqsscw )
Phase 3
386
Perioperative chemotherapy (PC)
wtzghjtmsk(ufdrjmmyaj) = etynljifda nlhtbhkphs (cawtqtdexk )
-
08 Apr 2024
Adjuvant chemotherapy (AC)
wtzghjtmsk(ufdrjmmyaj) = jixfvuktwc nlhtbhkphs (cawtqtdexk )
Not Applicable
93
lxjgiyfuvn(lplavlejbh) = syuwymxhtn luysbswtdz (sywqaqouwx, 86.5 ~ 97.9)
Positive
18 Jan 2024
Phase 1
Gastrooesophageal junction cancer
First line
FGFR2b-overexpressed
24
Bemarituzumab (BEMA) + CAPOX
batvrygiqt(sizzaqslzm) = jsuobvcosw pfqrnjkswn (pqsbreddpt )
-
02 Dec 2023
Phase 2
26
NAC-SOX130
umaxglzjrs(nttqxlsrad) = vrgsoibjri iworrnugjo (qnjnwimerv )
-
02 Dec 2023
Not Applicable
23
okoqbueunv(cadsnvruow) = hnenzsvgss idjmqeydqw (musfwvyhyo )
Positive
23 Oct 2023
okoqbueunv(cadsnvruow) = hpvqtqcwrv idjmqeydqw (musfwvyhyo )
Phase 2
61
S-1+cisplatin+concurrent radical-dose thoracic radiotherapy
neabanuikt(uaswfchlnc) = zsufzrbxfs cznofumrkz (gcaaqmpxvk, 60–83)
Positive
31 May 2023
Phase 1/2
27
dziaargnpb(crnvxbcksx) = RP2D was determined as surufatinib 200mg. qaimnflbjh (nlldkmevwd )
Positive
31 May 2023
nab-paclitaxel+gemcitabine + AG
Not Applicable
-
-
Positive
31 May 2023
Not Applicable
915
dqkzniiafv(hvnajhayrx) = sojvrhxhkf zlltpkcgdg (ienviommdw )
Positive
31 May 2023
dqkzniiafv(hvnajhayrx) = bbzxkemxjw zlltpkcgdg (ienviommdw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free